Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...
LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...
StockStory.org on MSN4d
Regeneron’s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock SoarsBiotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its ...
News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter ...
Regeneron (REGN) reported $3.79 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.3%. EPS of $12.07 for the same period compares to $11.86 a year ...
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy ... reflect those of Nasdaq, Inc. Founded in the ...
Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...
Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...
Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago.
Regeneron Pharmaceuticals earnings at a glance ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results